Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Gilead's Epclusa Approved As First Pan-Genotypic HCV Therapy

This article was originally published in The Pink Sheet Daily

Executive Summary

Fixed-dose combo of sofosbuvir and velpatasvir is approved to treat genotypes 1-6 and be the first ribavirin-free regimen for genotypes 2 and 3 of the virus.

Advertisement

Related Content

Quick Commercial Standouts Lacking Among 2016 US Launches
Gilead Admits It Needs M&A To Resume Growth, But Stays Quiet
Gilead's Epclusa: FDA Sought To Push Efficacy Bar Higher In Hepatitis C
Nearing Finish Line, HCV Race Focuses On Salvage Therapy
Bristol Stresses Cost Control Despite Strong Earnings Quarter
Bristol's HCV Bump Catalyzes Strong Quarter, But Not Expected To Last
Gilead Sees Prospects For Declining HCV Revenues To Stabilize

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS079556

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel